This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hereditary angioedema [HAE] / C1 esterase inhibitor deficiency / Defects in complement system유전성혈관부종 (C1에스터레이스억제인자결핍 / 보체계통의 결손)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D84.1 (Defects in complement system / C1 esterase inhibitor deficiency) | OMIM: #606860 (HAE1/HAE2, SERPING1) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsC1 esterase inhibitor deficiency, Defects in complement system, hereditary angioneurotic edema, HAE type 1 (decreased C1-INH antigen and function), HAE type 2 (decreased C1-INH function, normal antigen), C1-inhibitor deficiency, Hereditary angioneurotic edema (HANE)
C. Adult onsetPossible first onset in adulthood: yes — first symptoms are common around the teenage years, but first diagnosis in adulthood (30s–40s) is not uncommon; in adult women, first onset may be delayed and triggered by factors such as estrogen (oral contraceptives, pregnancy), stress, and surgery. Rarely, sporadic variants without family history are also diagnosed in adulthood.
1. History1888 first description by William Osler → 1963 Donaldson and Evans identify complement C1 inhibitor deficiency → 1972 Rosen et al. define HAE type 1/type 2 subtypes → 1980s–90s SERPING1 gene identified → since the 2000s, targeted therapies such as C1-INH concentrate, icatibant, and lanadelumab emerge.
2. CausesSERPING1 gene variant on chromosome 11 (11q12.1) → C1 inhibitor (C1-INH) deficiency (type 1) or loss of function (type 2) → overactivity of plasma kallikrein and factor XIIa → bradykinin overproduction → increased vascular permeability → localized edema attacks.
3. GeneticsAutosomal dominant (AD). More than 700 SERPING1 gene variants reported. 75% familial inheritance, 25% new variants. Persistently low blood C4 due to complement C4 consumption → diagnostic marker. Phenotypic variation due to estrogen response element.
4. General epidemiologyWorldwide prevalence 1/50,000–1/10,000. Several hundred patients estimated to be registered with rare disease status in Korea. Equal occurrence in men and women (however, symptom severity is higher in women due to estrogen effects). Average diagnostic delay 8–10 years.
5. PathophysiologyC1-INH deficiency → loss of inhibition of the contact activation pathway (factor XII→kallikrein→bradykinin) → bradykinin overproduction → B2 receptor binding → increased cAMP and opening of intercellular junctions → increased vascular permeability → tissue edema. C4 decreases due to overactivation of the classical complement pathway.
6. SymptomsRecurrent non-pruritic subcutaneous edema (extremities, face, genitals), intestinal mucosal edema (abdominal pain, vomiting, diarrhea), laryngeal and pharyngeal edema (dyspnea, life-threatening). Prodrome before attacks (erythematous skin changes, fatigue). Triggers: stress, trauma, estrogen, ACE inhibitors.
7. SignsNon-pruritic, non-erythematous subcutaneous edema. Decreased serum C4 (at baseline and between attacks). Decreased C1-INH antigen (type 1) or decreased function (type 2). Normal C1q (differentiates from acquired angioedema). Ascites and bowel wall edema on abdominal CT during attacks.
8. ScreeningMeasure serum C4 in patients with recurrent angioedema or abdominal pain (initial screening). If C4 is low, test C1-INH antigen and function. Children with family history: measure C4 and C1-INH after 12 months of age (after loss of maternally transferred antibodies). Confirm with SERPING1 gene analysis.
9. DiagnosisClassify with 3 tests: C4 (low) + C1-INH antigen (low in type 1 / normal in type 2) + C1-INH function (low in both types 1 and 2). Confirm SERPING1 gene variant. Normal C1q differentiates from acquired angioedema (low C1q). Confirm lack of response to antihistamines and steroids.
10. TreatmentAcute attacks: C1-INH concentrate (intravenous) or icatibant (subcutaneous, bradykinin B2 receptor antagonist) or ecallantide (kallikrein inhibitor). Long-term prophylaxis: lanadelumab (subcutaneous, anti-kallikrein monoclonal antibody), berotralstat (oral kallikrein inhibitor), subcutaneous C1-INH. Short-term preoperative prophylaxis: intravenous C1-INH.
11. PrognosisWithout adequate treatment, risk of death from asphyxiation due to laryngeal edema (historical mortality ~30%). Mortality markedly reduced with modern treatment. Attack frequency and severity vary widely between individuals, and lifelong management is needed. Intensive management required during pregnancy and the perioperative period. Reduced quality of life and accompanying depression and anxiety are common.
12. PreventionGenetic counseling and family screening. Avoid ACE inhibitors and estrogen preparations. Manage attack triggers (stress, infection, trauma). Always carry an emergency self-injection kit. Maintain long-term prophylactic treatment. Educate medical staff and people nearby.
13. ReferencesBusse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med. 2020 … and 9 other papers

1. History

The history of Hereditary Angioedema (HAE) dates back to the late 19th century. In 1882, the German internist Heinrich Quincke systematically described acute subcutaneous and mucosal edema occurring without allergic reaction, and named it "angioneurotic edema." However, it was the eminent Canadian-born internist William Osler who, in 1888, first clearly distinguished its non-pruritic, non-allergic features and first described it as familial. Reporting a family case spanning five generations, Osler argued that this disease was a distinct entity different from allergic urticaria or anaphylaxis.

The decisive turning point in elucidating the pathophysiology came in 1963, when Virginia Donaldson and Fred Evans discovered that C1 esterase inhibitor (C1-INH) was absent or markedly decreased in the serum of HAE patients. This discovery was the first to prove that HAE is caused by a deficiency of a regulatory protein of the complement system, and it subsequently became an important milestone in research on the pathophysiology of HAE (PMID: 14018540). In 1972, Rosen et al. proposed a clinical subtype classification distinguishing patients with decreased serum C1-INH antigen (type 1, about 85% of all cases) from patients with normal or elevated antigen but loss of function (type 2, about 15%).

The molecular genetic basis was established over the 1980s–90s. The SERPING1 (Serine Protease Inhibitor, Clade G, Member 1) gene encoding C1-INH was found to be located on chromosome 11 (11q12.1), and an autosomal dominant mode of inheritance and hundreds of heterozygous pathogenic variants were identified. After bradykinin was identified as the key mediator of HAE in the 1990s, the kallikrein-kinin pathway emerged as a therapeutic target.

In the 21st century, drug development advanced dramatically. In 2009, the US FDA approved plasma-derived C1-INH concentrate (Berinert) and the kallikrein inhibitor ecallantide (Kalbitor) for treatment of acute attacks, and in 2011 the bradykinin B2 receptor antagonist icatibant (Firazyr). In 2018, the anti-kallikrein monoclonal antibody lanadelumab (Takhzyro) was approved for long-term prophylaxis, and in 2020 the oral kallikrein inhibitor berotralstat (Orladeyo) was approved, greatly improving patients' access to treatment. In 2023–2024, new prophylactic agents such as garadacimab, which targets activated factor XII (factor XIIa), have obtained approval or are in clinical trials.


2. Causes

HAE is caused by heterozygous pathogenic variants in the SERPING1 gene located on the long arm of chromosome 11 (11q12.1), resulting in decreased blood levels (type 1) or loss of function (type 2) of C1 esterase inhibitor (C1-INH). C1-INH is a single-chain glycoprotein (molecular weight about 105 kDa) belonging to the serine protease inhibitor (serpin) family, and is a key inhibitor that simultaneously regulates the plasma contact activation pathway and the classical complement pathway.

C1-INH normally inhibits the following target enzymes: complement C1r and C1s (initiation step of the classical pathway), activated factor XII (Hageman factor, contact activation pathway), plasma kallikrein (kinninogenase), coagulation factor XI, and tissue plasminogen activator-related enzymes. Of these, the inhibitory function on the kallikrein-bradykinin pathway is key to the development of HAE. When C1-INH is deficient or loses function, factor XIIa and kallikrein become excessively activated, and high-molecular-weight kininogen (HK) is cleaved, generating large amounts of bradykinin, a peptide that causes vasodilation and increased permeability.

The mode of inheritance is autosomal dominant, and the disease is expressed through a haploinsufficiency mechanism in which a single normal allele alone cannot produce sufficient C1-INH. About 75% of all patients inherit the variant from one parent, and about 25% arise from new (de novo) variants. To date, more than 700 different pathogenic variants have been reported in the SERPING1 gene, including various types such as point mutations, deletions, insertions, and splicing variants. Some variants show a founder effect, being observed more commonly in specific ethnic groups.

Estrogen is known to suppress hepatic synthesis of C1-INH and increase factor XII expression, thereby exacerbating HAE attacks. For this reason, oral contraceptive use, pregnancy, and estrogen replacement therapy are strong triggers of HAE attacks. ACE (angiotensin-converting enzyme) inhibitors inhibit the breakdown of bradykinin and can trigger or worsen attacks in HAE patients, so they must be absolutely avoided. Apart from HAE, genetic deficiencies of other components of the complement system (C2, C3, C5–C9, factor D, factor P, etc.) may also fall within the broad scope of D84.1, but these have different clinical features and require separate consideration.


3. Genetics

HAE follows an autosomal dominant mode of inheritance. The causative gene SERPING1 is located on the long arm of chromosome 11 (11q12.1), consists of 8 exons and 7 introns, and encodes C1-INH, a glycoprotein with a molecular weight of about 105 kDa. The OMIM entry numbers are #606860 (HAE1) and #606860 (HAE2). As it is an autosomal dominant disease, if one parent is affected, each child has a 50% probability of being affected.

The spectrum of SERPING1 gene variants is very diverse. In type 1 HAE (about 85% of all cases), nonsense variants, frameshift variants, splicing variants, and large deletions that reduce protein expression in the SERPING1 gene predominate, and the protein produced from the variant allele is not secreted or is degraded within the cell. In type 2 HAE (about 15%), mainly missense variants are observed; in particular, variants altering the reactive center loop (RCL) region or the β-sheet A region produce loss-of-function proteins. These nonfunctional proteins are present in the blood at normal or increased levels and may appear normal on C1-INH antigen testing.

As a feature of the gene structure, numerous Alu repeat sequences about 350 base pairs long are distributed within SERPING1, so deletion variants due to unequal crossover are relatively more common than in other genes. In addition, an estrogen response element is present in the SERPING1 promoter, so that when estrogen levels rise, C1-INH synthesis is suppressed and factor XII expression increases, producing hormone-dependent phenotypic variation with increased attack risk. This is one of the reasons why female patients with the same variant show higher attack frequency or a more severe clinical picture than male patients.

Deficiencies of complement components other than C1-INH are also included in the D84.1 category. These include C2 deficiency (the most common complement deficiency, associated with SLE-like syndrome), C3 deficiency (recurrent pyogenic infections, immune complex disease), C5–C9 deficiency (susceptibility to Neisseria infection), and properdin (factor P) deficiency (X-linked recessive, susceptibility to meningococcal infection). These diseases are each caused by variants in the respective complement protein gene (C2 gene 6p21.3, C3 gene 19p13.3, etc.), and are clinically and pathophysiologically distinct from HAE.


4. General epidemiology

The worldwide prevalence of HAE is about 1/50,000–1/10,000, and it is estimated that there are about 100,000–300,000 patients worldwide. It occurs equally in men and women, but due to estrogen effects, women tend to have higher symptom severity and more frequent attacks. Differences in incidence between races are not clearly known, but some regional concentration of specific variants due to SERPING1 founder effects has been reported.

Diagnostic delay is an important epidemiological problem in HAE. According to international studies, the average delay from first symptom onset to confirmed diagnosis is about 8–10 years, and during this period patients often receive various misdiagnoses such as allergic reactions, abdominal emergencies, and psychogenic disorders. In particular, abdominal attacks sometimes lead to unnecessary invasive procedures such as surgical laparotomy or endoscopy. Early diagnosis and proper treatment can greatly reduce this waste of medical resources and burden on patients.

In Korea, according to epidemiological studies based on Health Insurance Review & Assessment Service (HIRA) data, the number of registered HAE patients is estimated at several hundred, and relatively fewer diagnosed patients have been reported than in Europe or North America, suggesting possible underdiagnosis. In Korea, through the Special Copayment Reduction V111 program, the copayment rate for medical expenses is lowered to 10% for 5 years after registration, and additional support is also available through the rare disease medical expense support program. Domestic published case reports and small cohort studies have confirmed the efficacy of C1-INH concentrate and icatibant.

The socioeconomic burden of HAE is also considerable. Unpredictable attacks severely restrict work, school, and social activities, and attacks entail high medical expenses such as emergency room visits, hospitalization, and surgical procedures. In quality-of-life studies, HAE patients are reported to show a notable decline in quality of life even among chronic diseases, due to fear of attacks, occupational limitations, and depressive and anxiety disorders. Accordingly, research on the need for and cost-effectiveness of long-term prophylactic treatment is actively under way.


5. Pathophysiology

The key pathogenic mechanism of HAE is increased vascular permeability due to bradykinin overproduction. Under normal conditions, C1-INH covalently inhibits activated factor XII (factor XIIa) and plasma kallikrein at the initiation step of the plasma contact activation pathway. Without this inhibition, factor XIIa converts prekallikrein to active kallikrein, and active kallikrein cleaves high-molecular-weight kininogen (HK) to generate bradykinin. When C1-INH is deficient or has lost function, and triggers such as surgery, trauma, infection, estrogen, or stress excessively activate this pathway, large amounts of bradykinin are generated.

Excess bradykinin binds to bradykinin B2 receptors on the surface of vascular endothelial cells, inducing increased intracellular cAMP, activation of protein kinase C, and promotion of NO (nitric oxide) synthesis. This signaling process loosens the junctions between vascular endothelial cells (tight junctions, adherens junctions), allowing plasma proteins and fluid to leak out of the vessels into the tissues. The half-life of bradykinin is normally very short (about 30 seconds), but excessive production in local tissues can cause edema attacks lasting 2–72 hours. In particular, when this process occurs in the laryngeal mucosa, there is a risk of asphyxiation due to airway obstruction.

C1-INH also inhibits C1r and C1s of the classical complement pathway. In C1-INH deficiency, C1 becomes excessively activated and C4 and C2 are consumed, resulting in persistently decreased serum C4 levels. Low serum C4 persists even between attacks and is used as a screening biomarker for HAE. C2 is also decreased but not as consistently as C4. C3 is usually normal, and regardless of classical pathway C4 decrease, C3 is maintained at normal levels through the alternative pathway. This complement profile helps differentiate acquired C1-INH deficiency (C1q also decreased) from HAE (normal C1q).

Bradykinin-mediated edema does not respond to antihistamines or corticosteroids. This means that HAE is fundamentally different pathophysiologically from histamine-mediated urticaria and angioedema in allergic reactions. Therefore, administering epinephrine, antihistamines, or steroids during acute HAE attacks is ineffective and may instead delay treatment. Kallikrein inhibitors (ecallantide, berotralstat), B2 receptor antagonists (icatibant), and C1-INH replacement, developed based on this pathophysiological understanding, are currently used as standard treatment.


6. Symptoms

The main clinical symptom of HAE is recurrent, unpredictable edema attacks, which are divided into cutaneous edema, abdominal attacks, and laryngeal attacks according to the site. Cutaneous edema is the most common symptom, appearing in subcutaneous tissues such as the hands, feet, face, limbs, and genitals. Unlike allergic angioedema, it is characterized by the absence of pruritus (itching) and is not accompanied by erythema. The edema peaks within hours and resolves spontaneously over 2–5 days even without treatment. In some patients, nonspecific prodromal symptoms such as an erythematous skin rash (similar to erythema marginatum), fatigue, and mood changes appear several hours or several days before an attack.

Abdominal attacks account for about 25–30% of all attacks, and intestinal mucosal edema causes severe abdominal pain, nausea, vomiting, and diarrhea. The pain is so severe that it is difficult to differentiate from acute abdominal emergencies (bowel obstruction, appendicitis, ruptured ovarian cyst, etc.), and unnecessary abdominal surgery is sometimes performed without proper diagnosis. Ascites and bowel wall edema may be observed on abdominal ultrasound or CT, which helps diagnose abdominal attacks. HAE must be included in the differential diagnosis of patients with recurrent abdominal pain of unknown cause without triggers.

Laryngeal attacks account for about 1–2% of all attacks, but they are the most serious, life-threatening complication because of the risk of asphyxiation from airway obstruction. They present with hoarseness, dysphagia, throat discomfort, and progressively worsening dyspnea, and if they progress without treatment, complete airway obstruction can cause death. Historically, about 30% of untreated HAE patients died of laryngeal edema. For this reason, all HAE patients should always carry emergency self-injectable medication and receive emergency treatment immediately when symptoms of a laryngeal attack occur.

Triggers of attacks include physical trauma (dental procedures, surgery, endoscopy, etc.), infection (especially upper respiratory infection), emotional stress, estrogen (oral contraceptives, pregnancy, hormone replacement therapy), ACE inhibitor use, and excessive physical activity. However, attacks occurring spontaneously without triggers are also common. Attack frequency varies widely between individuals, ranging from patients with attacks once a month or more to patients with attacks less than once a year.


7. Signs

On physical examination during an HAE attack, non-pruritic, non-erythematous subcutaneous edema is observed. The edema tends to have somewhat indistinct borders and to be non-pitting. The overlying skin is of normal color or slightly pale, and urticaria or erythema commonly seen in allergic angioedema is not present. With laryngeal and pharyngeal edema, hoarseness, inspiratory stridor, and dyspnea are observed.

The most important serum test finding is low C4. C4 remains persistently low at 30–50% of normal or less even between attacks, and decreases further during attacks. This is due to chronic hypoactivation of the classical complement pathway caused by C1-INH deficiency. In type 1 HAE, C1-INH antigen (protein level) is also decreased (less than 30% of normal), and in type 2 HAE, C1-INH antigen is normal or elevated, but C1-INH function (measured by chromogenic substrate or radioimmunodiffusion) is decreased to less than 50%. C1q remains normal in HAE, which is used to differentiate it from acquired C1-INH deficiency, in which C1q is decreased.

During abdominal attacks, abdominal CT may show ascites, bowel wall edema, and bowel dilation. The possibility of HAE should be considered in patients in whom these imaging findings appear repeatedly. Hematologically, hemoconcentration may occur during attacks, and hematocrit may rise. Complete blood count, liver function tests, kidney function tests, and thyroid function tests are usually normal. In acquired angioedema, C1q is also decreased due to C1-INH consumption by underlying lymphoma or autoimmune disease, whereas in HAE C1q is normal.


8. Screening

The initial screening test for HAE is serum C4 measurement. C4 remains persistently low even between attacks, making it useful as a screening biomarker. C4 must be measured in patients who have experienced recurrent non-pruritic angioedema, recurrent unexplained abdominal pain, or laryngeal edema. If C4 is low (less than 50% of the normal reference value), C1-INH antigen and function tests are additionally performed to differentiate HAE type 1 or type 2.

In children with a family history, it is recommended to perform C4, C1-INH antigen, and C1-INH function tests after 12 months of age (after maternally transferred antibodies have sufficiently disappeared). In some cases, C4 and C1-INH levels appear normal in childhood and decrease only in adolescence or adulthood, so HAE should not be excluded based on a single normal result, and follow-up testing is necessary. SERPING1 gene analysis is performed when the clinical diagnosis is uncertain or confirmation is needed, or for family carrier testing and prenatal diagnosis.

Diseases to be differentiated at the screening stage include allergic angioedema (accompanied by urticaria, responsive to antihistamines, IgE-mediated), acquired C1-INH deficiency (low C1q, underlying lymphoma or autoimmune disease), estrogen-dependent HAE (normal C1-INH, normal C4), and factor XII variant HAE (normal C1-INH and C4). C1q measurement must be included to differentiate from acquired angioedema. Checking history of ACE inhibitor use, history of oral contraceptive use, and whether attacks respond to antihistamines and steroids also helps the differential diagnosis.


9. Diagnosis

The standard diagnosis of HAE is made by a combination of clinical findings, serum complement tests, and genetic analysis. The 3 diagnostic tests are serum C4, C1-INH antigen, and C1-INH function. In type 1 HAE, low C4 + low C1-INH antigen + low C1-INH function are observed. Type 2 HAE is characterized by low C4 + normal or elevated C1-INH antigen + low C1-INH function. C1-INH function is measured by chromogenic substrate assay or radial immunodiffusion, and a functional level less than 50% of normal is judged a significant decrease.

C1q measurement is essential for differentiation from acquired C1-INH deficiency. In HAE, C1q is normal; this is because HAE is caused by congenital insufficient C1-INH synthesis (gene variant), whereas in acquired C1-INH deficiency, C1q also decreases due to consumption by autoantibodies against C1-INH or underlying lymphoma. SERPING1 gene sequencing is used for confirmation and family screening, and is performed by panel NGS or Sanger sequencing. Large deletions or structural variants can be detected by MLPA (multiplex ligation-dependent probe amplification).

Clinical diagnostic criteria (2018 WAO/EAACI guidelines) require the following: (1) recurrent (2 or more) non-pruritic, non-urticarial angioedema or (2) recurrent episodes of unexplained abdominal pain or laryngeal edema, and (3) serum abnormalities of low C4 and low C1-INH antigen or function, or (4) confirmation of a SERPING1 pathogenic variant. The fact that it does not respond to antihistamines, steroids, or epinephrine also supports the diagnosis of HAE. In children, attacks before school age are rare and may present as nonspecific abdominal pain, so diagnosis tends to be delayed; therefore, preemptive testing is recommended when there is a family history.


10. Treatment

HAE treatment is divided into acute attack treatment and long-term prophylactic treatment. The principle of acute attack treatment is to administer specific therapy as early as possible (within 1 hour of attack onset) to minimize the progression and duration of the attack. Currently approved acute attack treatments are as follows: Plasma-derived C1-INH concentrate (intravenous, Berinert/Ruconest) directly replaces the deficient C1-INH and suppresses bradykinin generation. Icatibant is a bradykinin B2 receptor antagonist that can be self-injected subcutaneously, and symptom improvement is expected within about 2 hours of administration. Ecallantide is a plasma kallikrein inhibitor administered by subcutaneous injection, but because of the risk of anaphylaxis it must be administered in a medical institution. Epinephrine, antihistamines, and steroids are ineffective for HAE, so their use alone should be avoided.

A laryngeal attack is an emergency; if possible, administer C1-INH concentrate or icatibant immediately, and if airway obstruction is imminent, prepare for endotracheal intubation or surgical airway. All HAE patients should always carry emergency self-injectable medication (icatibant or subcutaneous C1-INH formulation) and receive self-injection training.

Long-term prophylactic treatment is recommended for patients with frequent attacks (2 or more per month), a history of severe or life-threatening attacks, or markedly reduced quality of life. Lanadelumab (Takhzyro) is an anti-kallikrein monoclonal antibody administered by subcutaneous injection every 2–4 weeks, and in a randomized controlled trial it reduced attack frequency by about 80% compared with the control group. Berotralstat (Orladeyo) is an orally available kallikrein inhibitor whose preventive effect on attacks has been demonstrated with once-daily dosing. Subcutaneous C1-INH (Haegarda) can also be used for prophylaxis. Attenuated androgens (danazol, stanozolol) and tranexamic acid used in the past are now recommended as second-line options or to be avoided due to adverse effects. Before triggering procedures such as surgery, dental procedures, and endoscopy, intravenous C1-INH administration 1 hour before the procedure is recommended as short-term prophylaxis.


11. Prognosis

With modern treatment, mortality from HAE has decreased greatly. Historically, mortality from laryngeal attacks in untreated HAE patients reached about 30%, but now that proper diagnosis and access to emergency medications have improved, mortality from laryngeal attacks has fallen markedly. However, in patients whose diagnosis is delayed or who cannot access medication, the risk of death from laryngeal attacks still exists.

The frequency and severity of attacks vary greatly between patients. Some patients go through life with almost no attacks, whereas others have attacks 2–4 or more times per month, which seriously interferes with daily life. Pregnancy, surgery, estrogen use, and severe stress are major factors that increase attack frequency, so intensive monitoring and strengthened prophylactic treatment are needed during these periods. During pregnancy, C1-INH concentrate is used as the safest acute and prophylactic treatment.

Effectively managing attack frequency through long-term prophylactic treatment markedly improves quality of life. Long-term safety data for lanadelumab and berotralstat are generally favorable. Overall, HAE is a chronic disease requiring lifelong management, and proper diagnosis, patient education, ensuring access to emergency medications, and regular follow-up at a specialist clinic are key elements for improving prognosis. Psychological support is also important, as HAE patients experience persistent anxiety about attacks, limitations in work and social activities, and depressive and anxiety disorders at significantly higher rates than the general population.


12. Prevention

For primary prevention, genetic counseling and family screening of first-degree relatives of patients with confirmed HAE are key. Because HAE is autosomal dominant, 50% of a patient's children may be affected, and if this is unknown, a life-threatening laryngeal attack may occur during the diagnostic delay. C4, C1-INH antigen, C1-INH function tests, and SERPING1 gene testing should be performed on the siblings, children, and parents of confirmed patients. It is recommended that children of patients with confirmed HAE undergo screening tests after 12 months of age.

For secondary prevention (attack prevention), it is important to avoid known triggers. ACE inhibitors (captopril, enalapril, etc.) are never used, and oral contraceptives or estrogen-containing hormone therapy are avoided or used very cautiously. Short-term prophylactic treatment is given for triggering procedures such as dental procedures, surgery, and endoscopy. In patients with frequent attacks, long-term prophylactic treatment (lanadelumab, berotralstat, subcutaneous C1-INH) is started, and an emergency self-injection kit is always carried. Infection prevention (especially upper respiratory infection), stress management, and a regular lifestyle also help reduce attack frequency.

For tertiary prevention (minimizing complications), education of medical personnel and people nearby is important. Patients should carry an HAE medical certificate and emergency treatment protocol for emergency room staff, and be educated on how to respond immediately to a laryngeal attack. Treatment is optimized through regular follow-up with an immunology specialist and monitoring of treatment effects and adverse effects. Connecting with patient support groups (such as the Korea Rare Disease Foundation) to promote information sharing, psychological support, and social support also contributes to improved prognosis.


13. References

  1. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C'1-esterase. Am J Med. 1963;35:37-44. PMID: 14018540
  2. Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med. 2020;382(12):1136-1148. PMID: 32187470
  3. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc. 2012;33(Suppl 1):S145-156. PMID: 22794702
  4. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema — The 2021 revision and update. World Allergy Organ J. 2022;15(3):100627. PMID: 35479247
  5. Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress. J Allergy Clin Immunol. 2004;114(3 Suppl):S51-131. PMID: 15356535
  6. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112(1):58-64. PMID: 21296019
  7. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol. 2010;6(1):14. PMID: 20667121
  8. Longhurst HJ, Zanichelli A, Caballero T, et al. Comparing real-world use of intravenous and subcutaneous C1-esterase inhibitor and icatibant for acute hereditary angioedema attacks. Clin Exp Immunol. 2017;188(3):461-466. PMID: 28211569
  9. Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018;320(20):2108-2121. PMID: 30480729
  10. Zuraw B, Lumry WR, Johnston DT, et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164-172. PMID: 33516877